The c.265A>G variant in GP1BB is a missense variant predicted to cause substitution of Asparagine by Aspartic acid at amino acid 89 (p.Asn89Asp). This is a well known founder variant on the French Island of Reunion. This variant has been detected in at least 5 unrelated homozygous probands with Bernard-Soulier syndrome from the this island (PMID: 31997307, 1 PM3 points, PM3). At least one patient (Patient BSS1 in PMID: 31997307) with this variant had less than 10% expression of GPIba, GP1bb and GP9 measured by Western blot, which is highly specific for Bernard-Soulier syndrome. Additionally, the patient had excessive mucocutaneous bleeding and macrothrombocytopenia which are consistent with Bernard-Soulier syndrome (PP4). In both Family 2 and Family 3 of PMID: 31997307, the variant was reported to segregate in the proband plus 1 additional homozygous BSS affected sibling (2 points, PP1_Moderate). The computational predictor REVEL gives a score of 0.955, which is above the ClinGen PD VCEP threshold of >0.773 and predicts a damaging effect on GP1BB function (PP3_Moderate). This variant is absent from gnomAD v4.1.0 (PM2_Supporting). In summary, this variant meets the criteria to be classified as Likely Pathogenic for autosomal recessive Bernard-Soulier syndrome based on the ACMG/AMP criteria applied, as specified by the ClinGen PD VCEP: PM3, PP1_Moderate, PP3_Moderate, PP4 and PM2_Supporting (VCEP specifications version 1.1).